HALO compared with EVR: revenue, margins and what each company keeps, and the suppliers and customers both name

HALOHalozyme Therapeutics, Inc.

Mkt capRevenueRevenue

EVREvercore Inc.

Mkt capRevenueRevenue

Compare

HALOHalozyme Therapeutics, Inc.

EVREvercore Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only HALO 32

LLYEli Lilly and Company ("Lilly")customer

ABOSAcumen Pharmaceuticals, Inc. ("Acumen")customer

ARGXargenx BVBA ("argenx")customer

SKYESkye Bioscience, Inc. ("Skye Bioscience")customer

28 more · HALO chain ›

Shared 0

No shared counterparties.

Only EVR 1

—Glisco Managerunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

HALOHalozyme Therapeutics, Inc.

128.81▼−1.60%

Mkt cap$14.9BRevenue$481MQ2 FY26Revenue$1.4BFY25

EVREvercore Inc.

310.95▲+7.04%

Regular sessionSep 2 '83

Mkt cap$11.2BRevenue$2.9BQ2 FY26Revenue$11.5BFY25

Compare

Regular sessionSep 2 '83

HALOHalozyme Therapeutics, Inc.

EVREvercore Inc.

128.81▼−1.60%

Price

310.95▲+7.04%

$14.9B

Mkt cap

$11.2B

Q2 FY26$481M

Revenue

$2.9BQ2 FY26

FY25$1.4B

Revenue

$11.5BFY25

HALO128.81▼−1.60%vsEVR310.95▲+7.04%Regular sessionSep 2 '83